Back to Search
Start Over
Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low‐intensity chemotherapy in acute myeloid leukaemia.
- Source :
- British Journal of Haematology; Mar2021, Vol. 192 Issue 6, p1026-1030, 5p
- Publication Year :
- 2021
-
Abstract
- Summary: Based on promising results in older adults with acute myeloid leukaemia (AML), we treated patients with NPM1mut measurable residual disease (MRD) using off‐label venetoclax in combination with low‐dose cytarabine or azacitidine. Twelve consecutive patients were retrospectively identified, including five with molecular persistence and seven with molecular relapse/progression. All patients with molecular persistence achieved durable molecular complete remission (CRMRD‐) without transplantation. Six of seven patients with molecular relapse/progression achieved CRMRD‐ after 1–2 cycles of venetoclax. This paper highlights the promising efficacy of venetoclax‐based therapy to reduce the relapse risk in patients with persistent or rising NPM1mut MRD. [ABSTRACT FROM AUTHOR]
- Subjects :
- ACUTE myeloid leukemia
COMBINATION drug therapy
DISEASE relapse
OLDER people
Subjects
Details
- Language :
- English
- ISSN :
- 00071048
- Volume :
- 192
- Issue :
- 6
- Database :
- Complementary Index
- Journal :
- British Journal of Haematology
- Publication Type :
- Academic Journal
- Accession number :
- 149328732
- Full Text :
- https://doi.org/10.1111/bjh.16722